Enzyme replacement therapy for mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo B syndrome) has been hindered by inadequate mannose 6-phosphorylation and cellular uptake of recombinantly produced human α-and pH optimum of the fusion enzyme was much like those reported for rhNAGLU. hampering their ability to cross-correct tissues away from the injection and implantation sites. The M6P… Continue reading Enzyme replacement therapy for mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo B